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Background: Soya supplements are used in the treatment of neuropathic pain. Previous reports reveal
that consumption of soy diet before nerve injury prevents the development of neuropathic pain in rats.
Biochanin-A, a soy isoﬂavone, has a naturally occurring inhibitor of fatty acid amide hydrolase (FAAH)
that metabolized endocannabinoids.
Objective: The objective was to evaluate efﬁcacy of biochanin-A in streptozotocin (STZ) induced
neuropathic pain in rat model.
Materials and methods: Diabetes mellitus was induced by an injection of STZ at a dose of 45 mg/kg, i.v.
into tail vein of male albino Wistar rats. Biochanin-A was dosed at 0.1, 1 and 5 mg/kg by intraperitoneal
(i.p.) administration in diabetic neuropathic rats. Mechanical hyperalgesia and allodynia was measured
using RandalleSelitto analgesymeter and manual von Frey ﬁlaments of increasing weights respectively.
Paw withdrawal threshold (PWT) and percent PWT was determined with respect to both hyperalgesia
and allodynia.
Results: Treatment of biochanin-A at three different levels of 0.1, 1 and 5 mg/kg had not signiﬁcantly
altered serum glucose levels throughout the treatment period. In hyperalgesia study, acute treatment
with higher dose exhibited 51.1% reversal of paw withdrawal threshold (PWT) while with chronic
treatment, efﬁcacy declined to 22.5% reversal of PWT. In allodynia study, acute treatment reversed PWT
by 79.4% while with chronic treatment, efﬁcacy was raised to 88.2% reversal of PWT.
Conclusion: Biochanin-A demonstrated better efﬁcacy in reversing mechanical allodynia than mechan-
ical hyperalgesia. Biochanin-A could be a good drug candidate for further studies to establish the
mechanism of attenuation of neuropathic pain.
© 2016 Transdisciplinary University, Bangalore and World Ayurveda Foundation. Publishing Services by
Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Diabetes mellitus is a metabolic disorder manifested by hyper-
glycemia resulting from defects in insulin secretion, insulin action,
or both. The chronic hyperglycemia of diabetes is associated with
long-term damage, dysfunction, and failure of different organs,
especially the eyes, kidneys, nerves, heart and blood vessels [1]. The
total number of people with diabetes is projected to rise from 171
million in 2000 to 366 million in 2030 [2]. Recently, World Health
Organization (WHO) reportedly estimated 1.5 million deaths. Challa).
ary University, Bangalore.
alore and World Ayurveda Found
censes/by-nc-nd/4.0/).caused by diabetes [3]. Diabetes prevalence is alarmingly increasing
every year with large proportion of patients suffering from
neuropathic symptoms. Diabetic neuropathic pain states are really
devastating to a patient's quality of life in the long run. There is a
growing importance for the treatment of diabetic neuropathic pain
for which there are no appropriate treatment strategies. At present,
pharmacotherapy of neuropathic pain is largely limited to mainly
“off-label” use of drugs approved for other conditions, especially
tricyclic anti-depressants and anti-convulsants. Hence, study was
planned to address the problem of diabetic neuropathic pain in
animal models.
Bioﬂavonoids comprise a group of phenolic secondary plant
metabolites that are widespread in nature. Among bio-
ﬂavonoids, isoﬂavones are still being extensively studied to
indentify therapeutically active constituents in the area ofation. Publishing Services by Elsevier B.V. This is an open access article under the
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demonstrated to be beneﬁcial in experimental neuropathic pain
[4]. Biochanin-A, an O-methylated isoﬂavone, is a natural
organic compound in the class of phytochemicals known as
ﬂavonoids. Biochanin-A can be found in red clover in soy, in
alfalfa sprouts, in peanuts, in chick pea (Cicer arietinum) and in
other legumes [5]. Biochanin-A could provide beneﬁcial effects
for human health, including prevention of cancers, heart dis-
ease, menopausal symptoms, and osteoporosis [6]. Furthermore,
soya supplements are used in the treatment of neuropathic pain
[7]. Previous reports reveal that consumption of soy diet before
nerve injury prevents the development of neuropathic pain in
rats [8]. With remarkable beneﬁcial evidence of soy isoﬂavones
in neuropathic pain states, it is quite rational to explore possible
efﬁcacy of biochanin-A in animal models of neuropathic pain.
Hence, our investigation was aimed to evaluate the efﬁcacy of
biochanin-A, a soy isoﬂavone in streptozotocin (STZ) induced
neuropathic pain in rat models.
2. Materials and methods
2.1. Materials
STZ and biochanin-A were purchased from the Sigma Chem-
ical Company (St Louis, USA). Thiopentone sodium was supplied
by Abbott Lab Ltd (Ankleshwar, India). Gabapentin is the
generous gift sample from Sun Pharmaceuticals Ltd, Andheri, and
Mumbai. All other chemicals and reagents were used of analytical
grade.
2.2. Animals
Male albino Wistar rats (Mahaveera Enterprises Pvt Ltd,
Hyderabad, India) weighing 200e250 g were selected. Animals
were maintained under standard laboratory conditions at
25 ± 2 C, relative humidity 50 ± 15% and normal photoperiod
(12 h dark/light). Commercial pellet diet (Rayon's Biotechnology
Pvt Ltd, India) and water were provided ad libitum. The experi-
mental protocol was approved by the Institutional Animal Ethics
Committee (IAEC approved protocol number: KVSRSCOPS/11-03-
14-010) of KVSR Siddhartha College of Pharmaceutical Sciences,
Siddhartha Nagar, Vijayawada and animal experiments were car-
ried out as per Animal Regulatory Body of the Government (Regd.
No. 993/a/06/CPCSEA).
2.3. Experimental design
The rats were randomly divided into ﬁve groups with six ani-
mals each. Group 1, Normal control group treated with vehicle (5%
DMSO þ 10% Tween-80 þ 75% distilled water); Group 2, Diabetic
animals treated with biochanin-A (0.1 mg/kg, i.p.); Group 3, Dia-
betic animals treated with biochanin-A (1 mg/kg, i.p.); Group 4,
Diabetic animals treated with biochanin-A (5 mg/kg, i.p.); Group 5:
diabetic animals treated with Gabapentin (100mg/kg, i.p). Diabetes
induction day was considered as Day 0. Biochanin-A acute treat-
ment was given as a single dose on Day 21 of STZ induction and
pain parameters were assessed. Chronic treatment was given for
seven days following acute treatment and again on 8th day of
treatment, pain was assessed.
2.4. Induction of diabetes and neuropathic pain
Diabetes was induced by a single intravenous (i.v.) injection of
STZ, 45 mg/kg of body weight, dissolved in citrate buffer (pH 4.5),
into the tail vein of animals [9]. Diabetes was conﬁrmed after thethird day of STZ injection by estimating serum glucose using semi-
automatic analyser (Model: Erba Chem 5 plus V2; Transasia Bo-
medicals Ltd) and Erba Transasia glucose kit. Animals that devel-
oped serum glucose levels of more than 250 mg/dL were consid-
ered diabetic and included into the study. Following induction of
diabetes mellitus, animals were allowed for 21 days for the devel-
opment of neuropathic pain. On 22nd day, animals were evaluated
for the development of symptoms of mechanical hyperalgesia and
mechanical allodynia. Animals were considered to be neuropathic
when the same exhibited mechanical allodynia (i.e., paw with-
drawal or ﬂinching behaviour response to the application of a
bending force of less than 4 g) and mechanical hyperalgesia (i.e.,
paw withdrawal response was observed at a paw pressure of less
than or equal to 70 g).2.5. Determination of mechanical hyperalgesia
Mechanical nociceptive threshold or PWT, an index of me-
chanical hyperalgesia, was assessed by previously described
method [10]. The paw withdrawal threshold was quantiﬁed using
the RandalleSelitto paw pressure analgesymeter (model, 37215;
UGO Basile, Italy). Increasing pressure at a linear rate of 10 g/s was
applied to the centre of the hind paw. Pressure at which animal
withdraws its paw was recorded and expressed in mass units (g),
with a cut-off of 150 g to avoid potential tissue injury. PWT was
recorded for the left hind paw before and up to 4 h after treat-
ment. Percent reversal of PWT was determined using the formula:
[(Post-dose threshold  Pre-dose)/(Naive threshold  pre-dose
threshold)]  100.2.6. Determination of mechanical allodynia
The rats were placed individually in plastic cages with a
plastic mesh ﬂoor to determine withdrawal threshold. The ani-
mals were tested after acclimatization to the environment, typi-
cally 20e30 min after placement in the cage. The paw withdrawal
threshold in response to mechanical stimulation was measured
using the up and down method [11] by applying calibrated von
Frey ﬁlaments (Aesthesio®; Ugo basile, Italy) to the hind paw
from underneath the cage through openings in the mesh ﬂoor. A
series of von Frey ﬁlaments (0.4, 0.7, 0.16, 0.40, 0.60, 1.0, 1.4, 2.0,
4.0, 6.0, 8.0, 10, 15, 26 and 60 g) were applied vertically to the
plantar surface of the hind paw for 5 s while the hair was bent.
Brisk withdrawal of paw or paw ﬂinching was considered a
positive response. The absence of a response in the animals at a
pressure of 60 g was considered the cut off value. The stimulation
with one ﬁlament was repeated ﬁve times at 10e15 s intervals,
when lack of a response, the next ﬁlament with greater bending
force was applied. The lowest force required to elicit a paw
withdrawal response was recorded as the PWT (g). The animals
that exhibited paw withdrawal response or ﬂinching response at
less than 4 g were considered to have developed the allodynia.
Percent reversal of PWT was determined using the formula:
[(Post-dose threshold e Pre-dose)/(Naive threshold e pre-dose
threshold)]  100.2.7. Statistical analysis
The results were expressed as mean ± standard deviation (S.D).
Differences in PWT (both in hyperalgesia and allodynia) were
determined by twoway analysis of variance followed by Bonferroni
post hoc test. Differences at *p < 0.05, **p < 0.01, ***p < 0.001 were
considered statistically signiﬁcant.
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3.1. Effect of biochanin-A on serum glucose in control and treated
rats
Serum fasting glucose levels were estimated on Day 0, Day 7,
Day 14, Day 21 and Day 28. Fig.1 shows serum fasting glucose levels
in normal control, diabetic control and treatment groups.I.p.
administration of biochanin-A at three different dose levels of 0.1, 1
and 5 mg/kg has not signiﬁcantly altered serum glucose levels
throughout the treatment period.3.2. Effect of acute treatment of biochanin-A on mechanical
hyperalgesia
In all the animals, cut off PWT was 150 g. In normal control
rats, PWT was not signiﬁcantly altered. In diabetic control rats,
PWT declined from 150 g (naive) to 30 g (pre-dose). In
biochanin-A (0.1 mg/kg) treatment group, naive PWT, pre-dose
PWT, 1 h, 2 h, and 4 h post-dose PWT were found to be
143.33 ± 8.16, 41.67 ± 7.53, 53.33 ± 9.83, 52.50 ± 7.58 and
60.00 ± 8.37 respectively. In biochanin-A (1 mg/kg) treatment
group, naive PWT, pre-dose PWT, 1 h, 2 h, and 4 h post-dose PWT
were found to be 143.33 ± 8.16, 42.50 ± 5.24, 60.0 ± 9.49,
54.17 ± 7.36 and 55.00 ± 10.49 respectively. In biochanin-A
(5 mg/kg) treatment group, naive PWT, pre-dose PWT, 1 h, 2 h,
and 4 h post-dose PWT were found to be 143.33 ± 8.16,
43.33 ± 5.16, 73.33 ± 7.53, 65.83 ± 7.36 and 55.00 ± 5.48
respectively. The effect observed with biochanin-A in reversing
mechanical hyperalgesia was almost negligible though values
were statistically signiﬁcant (p < 0.001) at 1 h and 2 h post-dose.
The effect was neither dose dependent nor time dependent with
biochanin-A whereas Gabapentin (100 mg/kg, i.p) had shown
remarkable (p < 0.001) reversal of PWT at 1 h, 2 h and 4 h
post-dose when compared to pre-dose PWT. Peak effect was
observed at 1 h post-dose with Gabapentin (Fig. 2).Da
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Fig. 1. Effect of biochanin-A on serum fa3.3. Effect of chronic treatment of biochanin-A on mechanical
hyperalgesia
Fig. 3 shows PWT of animals in control and chronic treatment
groups. In all the animals, cut off PWT was 150 g. In normal control
rats, PWTwas not signiﬁcantly altered. In diabetic control rats, PWT
declined from 150 g (naive) to 30 g (pre-dose). In biochanin-A
(0.1 mg/kg) treatment group, naive PWT, pre-dose PWT, 1 h, 2 h,
and 4 h post-dose PWT were found to be 143.33 ± 8.16,
45.71 ± 3.60, 65.32 ± 8.74, 55.16 ± 6.34 and 60.04 ± 8.37 respec-
tively. In biochanin-A (1 mg/kg) treatment group, naive PWT,
pre-dose PWT, 1 h, 2 h, and 4 h post-dose PWT were found to be
150.00 ± 0.00, 54.92 ± 4.70, 84.21 ± 8.40, 90.24 ± 10.20 and
72.63 ± 8.34 respectively. In biochanin-A (5 mg/kg) treatment
group, naive PWT, pre-dose PWT, 1 h, 2 h, and 4 h post-dose PWT
were found to be 150.0 ± 0.00, 60.41 ± 7.98, 76.43 ± 9.34,
106.25 ± 8.32 and 84.12 ± 9.20 respectively. The effect observed
with biochanin-A was statistically signiﬁcant (p < 0.001) at 1 h 2 h
and 4 h post-dose whereas Gabapentin (100 mg/kg, i.p) had shown
remarkable (p < 0.001) reversal of PWTat 1 h, 2 h and 4 h post-dose
when compared to pre-dose PWT. Peak effect was observed at 1 h
post-dose with Gabapentin.3.4. Effect of acute treatment of biochanin-A on mechanical
allodynia
PWT of animals in allodynia test is presented in Fig. 4. In all
animals, cut off PWT was 60 g. In diabetic control rats, PWT
declined from 60 g (naive) to 4.3 g (pre-dose). In biochanin-A
(0.1 mg/kg) treatment group, naive PWT, pre-dose PWT, 1 h, 2 h,
and 4 h post-dose PWT were found to be 60.0 ± 0.0, 4.0 ± 1.6,
15.17 ± 5.85, 22.33 ± 5.68 and 22.33 ± 5.68 respectively. In
biochanin-A (1 mg/kg) treatment group, naive PWT, pre-dose PWT,
1 h, 2 h, and 4 h post-dose PWT were found to be 60.0 ± 0.0,
5.0 ± 1.10, 15.83 ± 8.21, 37.33 ± 17.56 and 22.33 ± 5.68 respectively.
In biochanin-A (5 mg/kg) treatment group, naive PWT, pre-doseDa
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Fig. 2. Effect of acute i.p. treatment of biochanin-A on mechanical hyperalgesia in diabetic neuropathic rats.
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Fig. 3. Effect of chronic i.p. treatment of biochanin-A on mechanical hyperalgesia in diabetic neuropathic rats.
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Fig. 4. Effect of acute i.p. treatment of biochanin-A on mechanical allodynia in diabetic neuropathic rats.
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5.0 ± 1.10, 17.83 ± 6.62, 48.67 ± 17.56 and 37.33 ± 17.56 respectively.
Biochanin-A had signiﬁcantly (p < 0.001) reversed PWT at 2 h and
4 h post-treatment. At all three doses, there was no signiﬁcant
reversal of PWT at 1 h post-treatment. The maximum reversal was
observed at 2 h post-dose at all doses but effect was almost
maintained at 4 h post-dose at higher dose whereas, the effect
declined 4 h post-dose with biochanin-A 0.1 mg/kg and 1 mg/kg
doses. Dose-dependent increase in the effect was observed with
increasing dose. Biochanin-A had reversed mechanical allodynia on
par with the standard drug, Gabapentin but the only difference was
that effect was delayed with biochanin-A.3.5. Effect of chronic treatment of biochanin-A on mechanical
allodynia
In all animals, cut off PWTwas 60 g. In diabetic control rats, PWT
declined from 60 g (naive) to 4.33 g (pre-dose). In biochanin-A
(0.1 mg/kg) treatment group, naive PWT, pre-dose PWT, 1 h, 2 h,
and 4 h post-dose PWT were found to be 60.0 ± 0.0, 12.71 ± 2.41,
23.69 ± 5.85, 35.24 ± 6.27 and 32.10 ± 5.68 respectively. In
biochanin-A (1 mg/kg) treatment group, naive PWT, pre-dose PWT,
1 h, 2 h, and 4 h post-dose PWT were found to be 60.0 ± 0.0,
15.86 ± 2.18, 27.13 ± 5.67, 40.74 ± 9.65 and 46.11 ± 7.83 respectively.
In biochanin-A (5 mg/kg) treatment group, naive PWT, pre-dose
PWT, 1 h, 2 h, and 4 h post-dose PWT were found to be 60.0 ± 0.0,
19.65 ± 3.24, 31.34 ± 7.16, 55.24 ± 10.28 and 56.81 ± 9.81 respec-
tively. Biochanin-A had signiﬁcantly (p < 0.001) reversed PWT at
1 h, 2 h and 4 h post-treatment at all dose levels. The maximum
reversal was observed at 2 h post-dose at all doses but effect was
almost maintained at 4 h post-dose at higher dose whereas, the
effect was not maintained and declined 4 h post-dose with
biochanin-A at 0.1 and 1 mg. Dose-dependent increase in the effect
was observed with increasing dose. Our results reveal that chronic
treatment exhibited superior anti-allodynic effect when compared
to acute treatment (Fig. 5).3.6. Effect of biochanin-A on percent reversal of hyperalgesia and
allodynia
Percent reversal was represented at 2 h post-dose following
treatment of biochanin-A. In hyperalgesia study, acute treatment
with biochanin-A at three different dose levels of 0.1, 1 and 5 mg/kgNa
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Fig. 5. Effect of chronic i.p. treatment of biochanin-A onhad shown percent reversals of PWT as 9.7, 37.1 and 51.1 respec-
tively while chronic treatment with biochanin-A at three different
dose levels of 0.1, 1 and 5 mg/kg had shown percent reversals of
PWT as 10.7, 11.6 and 22.5 respectively. In allodynia study, acute
treatment with biochanin-A at three different dose levels of 0.1, 1
and 5 mg/kg had shown percent reversals of PWT as 32.8, 58.7 and
79.4 respectively while chronic treatment with biochanin-A at
three different dose levels of 0.1, 1 and 5 mg/kg had shown percent
reversals of PWT as 47.6, 56.3 and 88.2 respectively. The result
clearly indicates that biochanin-A remarkably exhibiting higher
degree of efﬁcacy in the reversal of allodynia in comparison to
moderate efﬁcacy observed in reversing hyperalgesia (Fig. 6).4. Discussion
Streptozotocin is well reported for its selective pancreatic islet
b-cell cytotoxicity [12] and has beenwidely used to induce diabetes
mellitus in animals. Our results reveal that STZ injected rats
exhibited signiﬁcantly increased blood glucose levels as compared
with control rats.
The STZ induced diabetic rat [13,14] and mice [15] have
commonly been used as model of neuropathic pain with signs of
hyperalgesia and allodynia that may reﬂect signs observed in dia-
betic patients. In our study, i.v. administration of STZ (45 mg/kg
body weight) signiﬁcantly resulted in hyperglycemia. Altered
pattern of nociception may not be due to inherent neurotoxicity of
STZ [16], but STZ induced hyperalgesia clearly contributes to a wide
array of pathophysiological symptoms that can lead to altered
nociceptive responses tested in various animal models [15,17,18].
Our study results report that i.p. administration of biochanin-A
at three different dose levels of 0.1, 1 and 5 mg/kg did not signiﬁ-
cantly alter serum glucose levels throughout the treatment period.
Our result is in contrast to the previous ﬁnding of anti-
hyperglycemic effect of biochanin-A in terms of reduction in
glucose levels [19]. The discrepancy between these two studies
could possibly be attributed to variation in experimental design,
dose and route of administration. However, given that our aimwas
mainly to assess the mechanical hyperalgesia and mechanical
allodynia, we have estimated only serum glucose levels but not
focused on HbA1C and insulin.
Biochanin-A exhibited moderate effect in reversing mechanical
hyperalgesia while it elicited high degree of efﬁcacy in reversing
mechanical allodynia upon both acute and chronic treatment.2h
 po
st 
do
se
4h
 po
st 
do
se
Diabetic Control
Biochanin-A 0.1mg/kg,i.p
Biochanin-A 5 mg/kg,i.p
Gabapentin 100mg/kg,i.p
Biochanin-A 1mg/kg, i.p
*** ***
***
***
***
***
***
***
***
***
ay analysis of variance followed by Bonferroni post hoc test.
f diabetic control group. 
mechanical allodynia in diabetic neuropathic rat.
Hy
pe
alg
es
ia-
ac
ute
 st
ud
y
Hy
pe
alg
es
ia-
ch
ro
nic
 st
ud
y
all
od
yn
ia-
ac
ute
stu
dy
 
all
od
yn
ia-
ch
ro
nic
 st
ud
y
0
20
40
60
80
100
Biochanin-A 0.1mg,i.p
Biochanin-A 1 mg,i.p.
Biochanin-A 5 mg,i.p
9.7
37.1
51.1
10.7 11.6
22.5
32.8
58.7
79.4
47.6
56.3
88.2
At 2h post dose
%
 R
ev
er
sa
l o
f
Pa
w
 w
ith
dr
aw
al
 th
re
sh
ol
d
Fig. 6. Percent reversal of PWT at 2 h post-dose in acute hyperalgesia study, chronic hyperalgesia study, acute allodynia study and chronic hyperalgesia study. Percent reversal was
indicated at 2h post dose of Biochanin-A treatment.
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occurring inhibitor of FAAH, which metabolites endocannabinoids
[20]. However, the efﬁcacy of biochanin-A is higher at 2 h post-dose
in both hyperalgesia and allodynia. Our result is consistent with
earlier pharmacokinetic studies that demonstrate maximum con-
centrations (Tmax) of biochanin-A was observed in the range of
2e4 h. However, re-entry peaks of biochanin-A in the plasma were
observed, that are likely due to enterohepatic recirculation,
occurred at 4e5 h after oral administration of the 5 and 50 mg/kg
doses of biochanin-A [21,22]. In our study, biochanin-A was found
to be effective even at 4 h post-treatment. This indicates the results
are possibly correlating with the earlier pharmacokinetic studies
[21,22].
Similar study also demonstrated that kaempferol, isoﬂavone,
and related naturally occurring ﬂavonoids inhibit FAAH [23].
Another in-vitro study implied that inhibition of the cellular uptake
of anandamide by genistein and its analogue daidzein in cells with
different levels of FAAH-driven uptake was observed. This clearly
indicates that isoﬂavones have the ability to enhance the endo-
cannabinoids that are known to attenuate neuropathic pain states.
In 2004, McFarland et al. reported that the soy isoﬂavone genistein
could interfere with the cellular uptake of anandamide (AEA) [24].
Subsequent studies showed that property was shared by daidzein
and was due to the ability of the compounds to inhibit FAAH
[25,26].
In Asian countries, where soy consumption is higher than in
Western countries, serum concentrations of genistein and daidzein
can attain as high as 2e4 mM [27], implied that the concentrations
necessary for inhibition of FAAH are reachable in-vivo. Biochanin-A
was a mixed-type inhibitor of the rat FAAH and showed similar low
micromolar potencies towards rat, mouse and recombinant human
FAAH [20].
In another study, biochanin-Awas tested at doses of 30, 100 and
300 mg and was found to be effective in formalin induced ERK
phosphorylation in a manner antagonized by AM251. Thus,
biochanin-A behaved like URB597 after local administration to the
paw [20]. Thus, biochanin-A could be suitable drug candidate forneuropathic pain patients in alleviating majorly mechanical allo-
dynia and moderately mechanical hyperalgesia.
5. Conclusion
Biochanin-A demonstrates better efﬁcacy in reversing me-
chanical allodynia than in mechanical hyperalgesia. Biochanin-A
could be a deserved candidate for further studies to establish the
mechanisms in the area of neuropathic pain.
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